This is a Validated Antibody Database (VAD) review about human formyltetrahydrofolate dehydrogenase, based on 3 published articles (read how Labome selects the articles), using formyltetrahydrofolate dehydrogenase antibody in all methods. It is aimed to help Labome visitors find the most suited formyltetrahydrofolate dehydrogenase antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
formyltetrahydrofolate dehydrogenase synonym: 10-FTHFDH; 10-fTHF; FDH; FTHFD; cytosolic 10-formyltetrahydrofolate dehydrogenase; 10-formyltetrahydrofolate dehydrogenase; MER57B-ALDH1L1

Invitrogen
mouse monoclonal (7G8)
  • immunohistochemistry; human; 1:100; fig 4
Invitrogen formyltetrahydrofolate dehydrogenase antibody (eBioscience, 14-9595) was used in immunohistochemistry on human samples at 1:100 (fig 4). Brain (2016) ncbi
Abcam
mouse monoclonal
  • immunohistochemistry - paraffin section; human; 1:300
Abcam formyltetrahydrofolate dehydrogenase antibody (Abcam, ab56777) was used in immunohistochemistry - paraffin section on human samples at 1:300. Ann Neurol (2014) ncbi
Santa Cruz Biotechnology
mouse monoclonal (YY8)
  • immunohistochemistry; human; 1:100
In order to evaluate the expression of CD24, CD44, CD133 and ALDH1 in invasive ductal carcinoma of the breast, Santa Cruz Biotechnology formyltetrahydrofolate dehydrogenase antibody (Santa Cruz, SC-100497) was used in immunohistochemistry on human samples at 1:100. Pathol Res Pract (2015) ncbi
Articles Reviewed
  1. Chen A, Akinyemi R, Hase Y, Firbank M, Ndung u M, Foster V, et al. Frontal white matter hyperintensities, clasmatodendrosis and gliovascular abnormalities in ageing and post-stroke dementia. Brain. 2016;139:242-58 pubmed publisher
  2. KapucuoÄŸlu N, Bozkurt K, BaÅŸpınar Å, Koçer M, EroÄŸlu H, Akdeniz R, et al. The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer. Pathol Res Pract. 2015;211:740-7 pubmed publisher
  3. Schirmer L, Srivastava R, Kalluri S, Böttinger S, Herwerth M, Carassiti D, et al. Differential loss of KIR4.1 immunoreactivity in multiple sclerosis lesions. Ann Neurol. 2014;75:810-28 pubmed publisher